CombinatoRx Discovers Novel Multi-Target Mechanism for the Treatment of Hematologic Malignancies

-- New Findings Published In BLOOD Demonstrate Synergy Between A2A Agonist/PDE Inhibitors for the Treatment of Multiple Myeloma and Other B-Cell Malignancies --

-- Novel Synergy Discovered Through Systematic and Effective Combination High Throughput Screening Platform --

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the publication of new preclinical data in BLOOD, The Journal of the American Society of Hematology. In the article entitled, “Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies,” Rickles, et.al., Blood First Edition Paper, prepublished online April 9, 2010; DOI 10.1182/blood-2009-11-252668, CombinatoRx researchers, in collaboration with the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, demonstrate the powerful and unexpected synergistic interactions of A2A Agonist and PDE Inhibitors as potential adjunctive therapy to glucocorticoid (GC) containing regimens in the treatment of multiple myeloma (MM) and other B-cell malignancies.

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies,” said Paul G. Richardson, MD, Clinical Director, Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute and Associate Professor of Medicine, Harvard Medical School.

By deploying the CombinatoRx combination high throughput screening (cHTS) technology to identify compounds that synergize with GCs to inhibit the proliferation of the MM cells, researchers were able to identify two classes of targeted agents that synergize with GCs and quite strongly with each other. This synergy was observed broadly across a large panel of MM and diffuse large B-cell lymphoma (DLBCL) cell lines. Exposure of these cells to A2A agonists and specific PDE inhibitors results in rapid synergistic inhibition of proliferation and induction of apoptosis.

“These findings demonstrate the power of the CombinatoRx combination high-throughput screening (cHTS) technology to rapidly and systematically screen through thousands of single agents and combinations to discover novel and unexpected synergy with potential utility in a variety of proliferative diseases such as multiple myeloma and other B-Cell malignancies,” said Mark H.N. Corrigan, MD, President and CEO of CombinatoRx. “CombinatoRx is continuing to leverage the power of its proprietary platform through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaboration with Novartis.”

About CombinatoRx

CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its combination drug discovery capabilities and its selective ion-channel modulation platform to generate innovative therapeutics. To learn more about CombinatoRx, please visit www.combinatorx.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, the CombinatoRx cHTS drug discovery technology, and the business plans of CombinatoRx. These forward-looking statements about future expectations, plans, objectives and prospects of CombinatoRx may be identified by words like "believe," "expect," "may," "will," "should," "seek," or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx cHTS drug discovery technology, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the Company’s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(c) 2010 CombinatoRx, Incorporated. All rights reserved.



CONTACT:

CombinatoRx, Incorporated
Justin Renz, 617-301-7575
Senior Vice President and CFO
[email protected]
or
Gina Nugent, 857-753-6562
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Professional Services  Finance  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.